{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-24-000042","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.114587+00:00","generated_at":"2026-06-06T03:59:27.714848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024","bullets":["Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.","Jakafi FY23 net product revenue $2.59B (+8%); 2024 Jakafi guidance $2.69-$2.75B.","Opzelura FY23 net product revenue $338M (+162%) driven by atopic dermatitis and vitiligo launch.","GAAP FY23 net income $598M (diluted EPS $2.65); Non-GAAP net income $795M (diluted EPS $3.52).","Acquired worldwide rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys for $25M upfront."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-24-000042","json":"https://secwatch.observer/filing/0000879169-24-000042.json","markdown":"https://secwatch.observer/filing/0000879169-24-000042.md","text":"https://secwatch.observer/filing/0000879169-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/0000879169-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/incy-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:59:27.714848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f7ddcebe0ab31a5df4e470a3d265843fd306445","claim":"INCYTE CORP updated its fourth fiscal quarter and year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/0000879169-24-000042-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth fiscal quarter and year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}